{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.009324009324009324, 'mean_word_length': 5.458646616541353, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Corin as novel biomarker for myocardial infarction.

The study by Zhou et al . recently published in the J Am Coll Cardiol provides new insights into the prognostic utility of the novel biomarker corin for risk stratification of patients with acute myocardial infarction (AMI) (1). In this prospective cohort study comprising more than 1,300 patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI), low plasma corin concentrations were an independent predictor of major adverse cardiac events (MACE) defined as a composite endpoint of all-cause mortality, hospitalization for heart failure or recurrent AMI at a median follow-up duration of 634 days. This study impressively pointed out the incremental prognostic value of plasma corin concentrations in AMI patients beyond clinical characteristics and traditional cardiac biomarkers.